Is TB-500 detectable in drug tests?
Yes — TB-500 can be detected by specific WADA-context analytical methods designed for peptide-hormone detection. The compound and the parent thymosin β4 are on the WADA Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Detection capability depends on the specific analytical method used in a given testing context.
What the research literature says
TB-500 and the parent thymosin β4 fall within the scope of WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) which covers a broad category of peptide-class compounds with growth-factor or growth-modulating pharmacology. The actin-binding pharmacology characterised in the Yarmola work (PMID 11579089) and the integrin-linked kinase activation documented in the Bock-Marquette work (PMID 15565145) underlie the growth-factor-like classification.
Analytical detection methods for thymosin β4 and related peptide fragments have been developed for anti-doping contexts. The detection chemistry typically uses LC-MS/MS (liquid chromatography coupled to tandem mass spectrometry) with specific transitions selected for the parent peptide and characteristic backbone-cleavage fragments. Detection windows depend on dose, route of administration, and matrix (urine vs blood). The plasma half-life of the compound (~1.5-3 hours in rodent models) shapes the detection-window characteristics.
Researchers working in anti-doping-relevant research contexts should consult the most current WADA Prohibited List directly and the relevant analytical-method literature for the specific testing context. The detection landscape evolves as new methods are developed and validated.
Why this matters in research context
The WADA-detection question is relevant for researchers in sports-medicine, anti-doping, or analytical-chemistry research contexts. TB-500’s WADA status is well-established and the analytical-detection capability exists; the practical questions are about detection-window characterisation, dose-effect on detection thresholds, and the comparison between full-length thymosin β4 and the TB-500 fragment detection signatures.
Related compounds
- TB-500 10mg — the compound covered by this answer
- TB-500 (glossary entry) — structure, mechanism, regulatory framework
Related research questions
References
- Yarmola EG et al. Formation and implications of a ternary complex of profilin, thymosin beta 4, and actin. J Biol Chem 2001;276(49):46094-46101. [PMID 11579089]
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472. [PMID 15565145]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. TB-500 is sold strictly as a research-grade reagent for laboratory and bench research applications.